Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NEO212

Small molecule · Cytotoxic · developed by Neonc Technologies

Phase 1/2 Most advanced trial
NTHI Developer
1 Registered trials

What is NEO212?

NEO212 is an orally bioavailable conjugate of temozolomide, a prodrug alkylating agent, with perillyl alcohol. Temozolomide is converted to MTIC, which methylates tumor cell DNA, and the conjugate is reported to cross the blood-brain barrier. It is being studied in glioma, brain metastases, and a range of solid tumors including gastrointestinal, head and neck, gynecologic and melanoma indications.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
POH-TMZ
Drug type
Small molecule
Mechanism
Cytotoxic
Pathways
DNA methylation and DNA replication inhibition, apoptosis, FAK/Src signaling, epithelial-to-mesenchymal transition, autophagy
Therapy area
Oncology
Developer
Neonc Technologies, Inc. (NTHI)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06047379 Phase 1/2 Diffuse Astrocytoma, IDH-Mutant Recruiting NTHI

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Brain Metastases, AdultCervical CancerColorectal CancerDiffuse Astrocytoma, IDH-MutantEsophageal CancerEsophageal Squamous Cell CarcinomaGastric CancerGastroesophageal Junction AdenocarcinomaGlioblastoma, IDH-wildtypeHead and Neck Squamous Cell CarcinomaMelanomaMerkel Cell CarcinomaMicrosatellite Instability-High Colorectal CancerMicrosatellite Instability-High Solid Malignant Tumor

More from Neonc Technologies

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NTHI page.

Follow NTHI, the company behind NEO212

See NTHI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NTHI catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.